Next Article in Journal
A High Visceral-To-Subcutaneous Fat Ratio is an Independent Predictor of Surgical Site Infection after Gastrectomy
Previous Article in Journal
Trends in Diabetes-Related Potentially Preventable Hospitalizations in Adult Population in Spain, 1997–2015: A Nation-Wide Population-Based Study
Article Menu

Article Versions

Export Article

Open AccessReview
J. Clin. Med. 2019, 8(4), 493; https://doi.org/10.3390/jcm8040493

Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes

1
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
2
IQuity, Inc., Nashville, TN 37203, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 18 March 2019 / Revised: 6 April 2019 / Accepted: 8 April 2019 / Published: 11 April 2019
(This article belongs to the Section Immunology)
PDF [656 KB, uploaded 11 April 2019]

Abstract

Healthcare expenditures in the United States are growing at an alarming level with the Centers for Medicare and Medicaid Services (CMS) projecting that they will reach $5.7 trillion per year by 2026. Inflammatory diseases and related syndromes are growing in prevalence among Western societies. This growing population that affects close to 60 million people in the U.S. places a significant burden on the healthcare system. Characterized by relatively slow development, these diseases and syndromes prove challenging to diagnose, leading to delayed treatment against the backdrop of inevitable disability progression. Patients require healthcare attention but are initially hidden from clinician’s view by the seemingly generalized, non-specific symptoms. It is imperative to identify and manage these underlying conditions to slow disease progression and reduce the likelihood that costly comorbidities will develop. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders. The current total cost to the U.S. healthcare system is at least $90B dollars annually. Through unique analysis of financial cost drivers, this review identifies opportunities to improve clinical outcomes and help control these disease-related costs by 20% or more.
Keywords: multiple sclerosis; Crohn’s disease; ulcerative colitis; fibromyalgia syndrome; irritable bowel syndrome; disease-modifying therapy; diagnostics; direct costs; early diagnosis; inflammation multiple sclerosis; Crohn’s disease; ulcerative colitis; fibromyalgia syndrome; irritable bowel syndrome; disease-modifying therapy; diagnostics; direct costs; early diagnosis; inflammation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wylezinski, L.S.; Gray, J.D.; Polk, J.B.; Harmata, A.J.; Spurlock, C.F., III. Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. J. Clin. Med. 2019, 8, 493.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top